Page 201 - Haematologica - Vol. 105 n. 6 - June 2020

HRQoL with thalidomide and lenalidomide
Questionnaire Core 30. J Clin Oncol.
2011;29(1):89-96.
24. Cocks K, King MT, Velikova G, et al.
Evidence-based guidelines for interpreting change scores for the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30. Eur J Cancer. 2012; 48(11):1713-1721.
25. Facon T, Mary JY, Hulin C, et al. Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced- intensity autologous stem cell transplanta- tion in elderly patients with multiple myelo- ma (IFM 99-06): a randomised trial. Lancet. 2007;370(9594):1209-1218.
26. Hulin C, Facon T, Rodon P, et al. Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial. J Clin Oncol. 2009;27(22):3664-3670.
27. Wijermans P, Schaafsma M, Termorshuizen F, et al. Phase III study of the value of thalidomide added to melphalan plus pred- nisone in elderly patients with newly diag- nosed multiple myeloma: the HOVON 49 Study. J Clin Oncol. 2010;28(19):3160-3166.
28. Palumbo A, Hajek R, Delforge M, et al. Continuous lenalidomide treatment for newly diagnosed multiple myeloma. N Engl J Med. 2012;366(19):1759-1769.
29. Nielsen LK, Abildgaard N, Jarden M, Klausen TW. Methodological aspects of health-related quality of life measurement and analysis in patients with multiple myeloma. Br J Haematol 2019;185(1): 11-24.
30. Sterne JA, White IR, Carlin JB, et al. Multiple imputation for missing data in epidemiolog- ical and clinical research: potential and pit- falls. BMJ. 2009;338:b2393.
31. Beijers AJ, Vreugdenhil G, Oerlemans S, et al. Chemotherapy-induced neuropathy in multiple myeloma: influence on quality of life and development of a questionnaire to compose common toxicity criteria grading for use in daily clinical practice. Support Care Cancer. 2015;24(6):2411-2420.
32. Sprangers MA, Schwartz CE. Integrating response shift into health-related quality of life research: a theoretical model. Soc Sci Med. 1999;48(11):1507-1515.
33. Kvam AK, Wisloff F, Fayers PM. Minimal important differences and response shift in health-related quality of life; a longitudinal study in patients with multiple myeloma. Health Qual Life Outcomes. 2010;8:79.
34. Schuurhuizen C, Braamse AMJ, Konings I, et al. Does severe toxicity affect global qual- ity of life in patients with metastatic colorec- tal cancer during palliative systemic treat- ment? A systematic review. Ann Oncol. 2017;28(3):478-486.
35. Bottomley A, Pe M, Sloan J, et al. Analysing data from patient-reported outcome and quality of life endpoints for cancer clinical trials: a start in setting international stan- dards. Lancet Oncol. 2016;17(11):e510-e514.
36. Thanarajasingam G, Minasian LM, Baron F, et al. Beyond maximum grade: modernising the assessment and reporting of adverse events in haematological malignancies. Lancet Haematol. 2018;5(11):e563-e598.
37. Di Maio M, Gallo C, Leighl NB, et al. Symptomatic toxicities experienced during anticancer treatment: agreement between patient and physician reporting in three ran- domized trials. J Clin Oncol. 2015;33(8):910- 915.
38. Basch E, Iasonos A, McDonough T, et al. Patient versus clinician symptom reporting
using the National Cancer Institute Common Terminology Criteria for Adverse Events: results of a questionnaire-based study. Lancet Oncol. 2006;7(11):903-909.
39. Gravis G, Marino P, Joly F, et al. Patients' self-assessment versus investigators' evalua- tion in a phase III trial in non-castrate metastatic prostate cancer (GETUG-AFU 15). Eur J Cancer. 2014;50(5):953-962.
40. Le-Rademacher J, Kanwar R, Seisler D, et al. Patient-reported (EORTC QLQ-CIPN20) versus physician-reported (CTCAE) quan- tification of oxaliplatin- and paclitaxel/car- boplatin-induced peripheral neuropathy in NCCTG/Alliance clinical trials. Support Care Cancer. 2017;25(11):3537-3544.
41. Kulis D, Bottomley A, Whittaker C, et al. The use of the Eortc item library to supple- ment Eortc quality of life instruments. Value in Health. 2017;20(9).
42. Kluetz PG, Chingos DT, Basch EM, Mitchell SA. Patient-Reported Outcomes in Cancer Clinical Trials: Measuring Symptomatic Adverse Events With the National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). Am Soc Clin Oncol Educ Book. 2016; (36):67-73.
43. Basch E, Reeve BB, Mitchell SA, et al. Development of the National Cancer Institute's patient-reported outcomes ver- sion of the common terminology criteria for adverse events (PRO-CTCAE). J Natl Cancer Inst. 2014;106(9).
44. Pawlyn C, Khan MS, Muls A, et al. Lenalidomide-induced diarrhea in patients with myeloma is caused by bile acid malab- sorption that responds to treatment. Blood. 2014;124(15):2467-2468.
haematologica | 2020; 105(6)
1659